<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Shukla SA</dc:creator>
  <dc:creator>Bachireddy P</dc:creator>
  <dc:creator>Schilling B</dc:creator>
  <dc:creator>Galonska C</dc:creator>
  <dc:creator>Zhan Q</dc:creator>
  <dc:creator>Bango C</dc:creator>
  <dc:creator>Langer R</dc:creator>
  <dc:creator>Lee PC</dc:creator>
  <dc:creator>Gusenleitner D</dc:creator>
  <dc:creator>Keskin DB</dc:creator>
  <dc:creator>Babadi M</dc:creator>
  <dc:creator>Mohammad A</dc:creator>
  <dc:creator>Gnirke A</dc:creator>
  <dc:creator>Clement K</dc:creator>
  <dc:creator>Cartun ZJ</dc:creator>
  <dc:creator>Van Allen EM</dc:creator>
  <dc:creator>Miao D</dc:creator>
  <dc:creator>Huang Y</dc:creator>
  <dc:creator>Snyder A</dc:creator>
  <dc:creator>Merghoub T</dc:creator>
  <dc:creator>Wolchok JD</dc:creator>
  <dc:creator>Garraway LA</dc:creator>
  <dc:creator>Meissner A</dc:creator>
  <dc:creator>Weber JS</dc:creator>
  <dc:creator>Hacohen N</dc:creator>
  <dc:creator>Neuberg D</dc:creator>
  <dc:creator>Potts PR</dc:creator>
  <dc:creator>Murphy GF</dc:creator>
  <dc:creator>Lian CG</dc:creator>
  <dc:creator>Schadendorf D</dc:creator>
  <dc:creator>Hodi FS</dc:creator>
  <dc:creator>Wu CJ</dc:creator>
  <dc:date>2018</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">CTLA-4 immune checkpoint blockade is clinically effective in a subset of patients with metastatic melanoma. We identify a subcluster of MAGE-A cancer-germline antigens, located within a narrow 75 kb region of chromosome Xq28, that predicts resistance uniquely to blockade of CTLA-4, but not PD-1. We validate this gene expression signature in an independent anti-CTLA-4-treated cohort and show its specificity to the CTLA-4 pathway with two independent anti-PD-1-treated cohorts. Autophagy, a process critical for optimal anti-cancer immunity, has previously been shown to be suppressed by the MAGE-TRIM28 ubiquitin ligase in vitro. We now show that the expression of the key autophagosome component LC3B and other activators of autophagy are negatively associated with MAGE-A protein levels in human melanomas, including samples from patients with resistance to CTLA-4 blockade. Our findings implicate autophagy suppression in resistance to CTLA-4 blockade in melanoma, suggesting exploitation of autophagy induction for potential therapeutic synergy with CTLA-4 inhibitors.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/222791</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.cell.2018.03.026</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/29656892</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Cell. - 2018</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">CTLA-4</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">MAGE-A</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">PD-1</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">autophagy</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">cancer-germline antigen</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">checkpoint blockade</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">immunogenomics</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">immunotherapy</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">ipilimumab</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">melanoma</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Animals</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Antibodies, Monoclonal</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Antigens, Neoplasm</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Autophagy</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">CTLA-4 Antigen</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Cell Line, Tumor</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">DNA Methylation</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Epigenesis, Genetic</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Gene Expression Profiling</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Germ-Line Mutation</dc:subject>
  <dc:subject xmlns:ns22="xml" ns22:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns23="xml" ns23:lang="en">Immunotherapy</dc:subject>
  <dc:subject xmlns:ns24="xml" ns24:lang="en">Ipilimumab</dc:subject>
  <dc:subject xmlns:ns25="xml" ns25:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns26="xml" ns26:lang="en">Melanoma</dc:subject>
  <dc:subject xmlns:ns27="xml" ns27:lang="en">Melanoma-Specific Antigens</dc:subject>
  <dc:subject xmlns:ns28="xml" ns28:lang="en">Mice</dc:subject>
  <dc:subject xmlns:ns29="xml" ns29:lang="en">Mice, Transgenic</dc:subject>
  <dc:subject xmlns:ns30="xml" ns30:lang="en">Neoplasms</dc:subject>
  <dc:subject xmlns:ns31="xml" ns31:lang="en">Skin Neoplasms</dc:subject>
  <dc:title xmlns:ns32="xml" ns32:lang="en">Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
